Related Experiment Video
Updated: Nov 10, 2025
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
Molecular Chaperones in Osteosarcoma: Diagnosis and Therapeutic Issues
Morgane Lallier1, Louise Marchandet1, Brice Moukengue1
1UMR1238, Phy-OS, Sarcomes Osseux et Remodelage des Tissus Calcifiés, INSERM, Université de Nantes, 44035 Nantes, France.
Abstract:
Osteosarcoma (OS) is the most common form of primary bone tumor affecting mainly children and young adults. Despite therapeutic progress, the 5-year survival rate is 70%, but it drops drastically to 30% for poor responders to therapies or for patients with metastases. Identifying new therapeutic targets is thus essential. Heat Shock Proteins (HSPs) are the main effectors of Heat Shock Response (HSR), the expression of which is induced by stressors. HSPs are a large family of proteins involved in the folding and maturation of other proteins in order to maintain proteostasis. HSP overexpression is observed in many cancers, including breast, prostate, colorectal, lung, and ovarian, as well as OS. In this article we reviewed the significant role played by HSPs in molecular mechanisms leading to OS development and progression. HSPs are directly involved in OS cell proliferation, apoptosis inhibition, migration, and drug resistance. We focused on HSP27, HSP60, HSP70 and HSP90 and summarized their potential clinical uses in OS as either biomarkers for diagnosis or therapeutic targets. Finally, based on different types of cancer, we consider the advantage of targeting heat shock factor 1 (HSF1), the major transcriptional regulator of HSPs in OS.
Insights
Heat Shock Proteins (HSPs) drive osteosarcoma (OS) progression by promoting cell proliferation and drug resistance. Targeting HSPs or their regulator, heat shock factor 1 (HSF1), offers potential new therapies for this bone cancer.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Osteosarcoma (OS) is a primary bone cancer common in young adults.
- Current 5-year survival rates for OS are ~70%, dropping to 30% for metastatic or therapy-resistant cases.
- Identifying novel therapeutic targets is crucial for improving OS patient outcomes.
Purpose of the Study:
- To review the role of Heat Shock Proteins (HSPs) in osteosarcoma development and progression.
- To explore the potential of HSPs as diagnostic biomarkers and therapeutic targets in OS.
- To evaluate targeting heat shock factor 1 (HSF1) as a therapeutic strategy for OS.
Main Methods:
- Literature review of studies on HSPs and osteosarcoma.
- Analysis of HSP involvement in OS cell proliferation, apoptosis, migration, and drug resistance.
- Examination of clinical applications of HSP27, HSP60, HSP70, and HSP90 in OS.
Main Results:
- HSP overexpression is prevalent in OS and linked to tumor progression.
- Specific HSPs (HSP27, HSP60, HSP70, HSP90) are implicated in OS cell proliferation, apoptosis inhibition, migration, and drug resistance.
- HSPs show potential as diagnostic biomarkers and therapeutic targets for OS.
Conclusions:
- HSPs play a significant role in the molecular mechanisms of osteosarcoma.
- Targeting HSPs or HSF1 presents a promising therapeutic avenue for osteosarcoma treatment.
- Further research into HSP-targeted therapies could improve survival rates for OS patients.
Related Concept Videos
03:00Molecular Chaperones and Protein Folding
03:00Molecular Chaperones and Protein Folding
The...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...